Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429381 | 0.87 | PDGFRB (0.77) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL29540321 | 0.87 | PDGFRB (0.77) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL24113306 | 0.85 | FLT3 (0.68) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL30189510 | 0.85 | FLT3 (0.68) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL335655 | 0.85 | FLT3 (0.68) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL216170 | 0.84 | FLT3 (0.67) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL29368200 | 0.84 | FLT3 (0.67) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL30909089 | 0.83 | PDGFRB (0.58) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL24450250 | 0.81 | FLT3 (0.63) | FLT3PDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL24019644 | 0.81 | FLT3 (0.63) | FLT3PDGFRBPDGFRANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-7566736-B2 | Substituted indoles, compositions containing them, method for the production thereof and their use | AVENTIS PHARMA S.A. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1841762-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006061493-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259910-A1 | Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use | IDO1, RB1, IDO2 | FLT3 1038/4885PDGFRB 1177/4885PDGFRA 980/4885 |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | FLT3 3961/4885PDGFRB 3219/4885PDGFRA 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.